NCT04844086

Infusion of CD19-Specific Chimeric Antigen Receptor T-cells Produced by Rapid Personalized Manufacture for Patients With Advanced Lymphoid Malignancies

Study Summary

This is an open-label Phase 1 study to determine the feasibility, safety, and the recommended maximum tolerated Dose (MTD) of a single infusion of RPM CD19 mbIL15 CAR-T cells for adult patients. Approximately 24 subjects will be enrolled and it is anticipated approximately 16 subjects will be infused at the varied doses of T cells.

Want to learn more about this trial?

Request More Info

Interventions

RPM CD19-mbIL15-CAR-T cellsBIOLOGICAL
Single dose of RPM CD19-mbIL15-CAR-T cells will be infused, and a standard "3+3" design will be applied. Drug: Fludarabine Fludarabine is used for lymphodepletion. Drug: Cyclophosphamide Cyclophosphamide is used for lymphodepletion

Study Locations

FacilityCityStateCountry
National Taiwan University HospitalTaipeiTaiwan

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026